Benitec Biopharma Return on Investment 2014-2022 | BNTC
Current and historical return on investment (ROI) values for Benitec Biopharma (BNTC) over the last 10 years.
| Benitec Biopharma ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2022-09-30 |
$-0.02B |
$0.02B |
-189.47% |
| 2022-06-30 |
$-0.02B |
$0.00B |
-184.62% |
| 2022-03-31 |
$-0.02B |
$0.01B |
-188.89% |
| 2021-12-31 |
$-0.02B |
$0.01B |
-184.62% |
| 2021-09-30 |
$-0.02B |
$0.02B |
-152.38% |
| 2021-06-30 |
$-0.01B |
|
-164.71% |
| 2021-03-31 |
$-0.01B |
$0.01B |
-118.18% |
| 2020-12-31 |
$-0.01B |
$0.02B |
-133.33% |
| 2020-06-30 |
$-0.01B |
$0.01B |
-96.00% |
| 2020-03-31 |
$-0.01B |
|
-133.33% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.006B |
$0.000B |
|
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
|
